Complications and outcomes in XXXX .

@entity1 @entity1169 @entity82 @entity3182 @entity548 @entity11884 @entity843 @entity409 @entity1761 @entity3080 @entity1405 @entity8508 @entity2312 @entity99
PURPOSE OF REVIEW: @entity409 ( @entity409 ) causes significant morbidity and mortality, mainly due to complications [ @entity99 , @entity843 , @entity3182 ( @entity3182 ) and esophageal @entity548 (EVH)]. Studies of the complications, management and outcomes in @entity1 with @entity409 over the last 18 months are reviewed. RECENT FINDINGS: Predictors of response to @entity11884 therapy in @entity99 have been reported, along with the effect of minimal @entity99 on driving. @entity1761 was found to lead to better maintenance of remission and decreased readmission rates in @entity1 with @entity82 and @entity99 . Satavaptan (a vasopressin receptor antagonist) was investigated for treatment of refractory @entity843 and appeared to be effective, but this compound is not currently approved by the US Food and Drug Administration (FDA). @entity1 with refractory @entity843 taking @entity1169 were found to have poorer outcomes than those not taking @entity1169 . @entity8508 currently appears to be the best medical therapy available for @entity1 with type 1 @entity3182 ; the addition with albumin to @entity8508 appeared to decrease mortality in @entity1 with type 1 @entity3182 . In primary prophylaxis of EVH, @entity1405 was found to reduce the rate of initial @entity548 compared with band ligation. Early transjugular intrahepatic portosystemic shunts placed in highly selected @entity1 with acute EVH and a high risk of endoscopic failure decreased long-term mortality. In @entity1 with @entity2312 , primary prophylaxis with @entity3080 may decrease the probability of gastric @entity548 compared with nonselective beta-blockers. SUMMARY: Refinement in clinical management strategies for @entity1 with @entity82 and its complications appear to continue to contribute to improved @entity1 outcomes.
